BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Iparomlimab and tuvonralimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Iparomlimab and tuvonralimab\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07290010-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07290010)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: The Efficacy an
 d Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemother
 apy as the First-line Treatment for Esophageal Squamous Cell Carcinoma\nEs
 timated primary completion: December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07290010
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07396324-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07396324)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Neoadjuvant QL1
 706 in Patients With Hormone Receptor Positive\, HER2-negative Breast Canc
 er\nEstimated primary completion: December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07396324
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892925-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT06892925)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 Combined
  With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Bili
 ary Tract Tumors\nEstimated primary completion: December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0689292
 5
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06809530-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Iparomlimab and tuvonralimab: Phase 1/2 readout est. (NCT06809530)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 1/2.\nStudy: Intrathecal D
 ual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed 
 for Leptomeningeal Metastasis\nEstimated primary completion: 1 December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-t
 uvonralimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06809530
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06787183-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT06787183)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: SCRT(Short Cour
 se Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver M
 etastases\nEstimated primary completion: 1 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06787183
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06751277-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT06751277)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 Combined
  with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial
  Cancer\nEstimated primary completion: 30 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06751277
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908382-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT06908382)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Neoadjuvant QL1
 706 Therapy for ESCC\nEstimated primary completion: 31 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonrali
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06908382
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07271602-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07271602)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Non-Small Cell Lung Ca
 ncer.\nStudy: A Phase 2 Randomized\, Controlled Trial of QL1706 Plus Chemo
 therapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lun
 g Cancer.\nEstimated primary completion: 31 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07271602
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07867392-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07867392)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Neoadjuvant Ipa
 romlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Ga
 stroesophageal Junction Cancer\nEstimated primary completion: 31 December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and
 -tuvonralimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07867392
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07291401-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07291401)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Radiotherapy Pl
 us CAPOX\, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therap
 y for LARC\nEstimated primary completion: 1 January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07291401
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06801665-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT06801665)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: FMT+ QL1706+Bev
 acizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal C
 ancer With Liver Metastasis\nEstimated primary completion: 1 February 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuv
 onralimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06801665
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06897046-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270225
DTEND;VALUE=DATE:20270226
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT06897046)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Non-Small Cell Lung Ca
 ncer.\nStudy: Perioperative Study of Iparomlimab and Tuvonralimab in Resec
 table NSCLC\nEstimated primary completion: 25 February 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06897046
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07172217-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07172217)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: The Efficacy an
 d Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recu
 rrent CC\nEstimated primary completion: 28 February 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07172217
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07049185-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07049185)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 Plus Cel
 ecoxib in Advanced Esophageal Squamous Cell Carcinoma\nEstimated primary c
 ompletion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07049185
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07113964-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07113964)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 With Ola
 parib for Previously Treated HER2-negative Breast Cancer Patients With Hom
 ologous Recombination Deficiency (HRD)\nEstimated primary completion: 30 M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlima
 b-and-tuvonralimab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07113964
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07205497-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07205497)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 Plus Neo
 adjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced
  Cervical Cancer\nEstimated primary completion: 30 March 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0720549
 7
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07453394-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Iparomlimab and tuvonralimab: Phase 1/2 readout est. (NCT07453394)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 1/2\, Non-Small Cell Lung 
 Cancer.\nStudy: QLS5132 Combination Therapy in Advanced Solid Tumors\nEsti
 mated primary completion: April 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07453394
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07139041-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07139041)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Non-Small Cell Lung Ca
 ncer.\nStudy: Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing 
 Conversion to Resectability in Initially Unresectable Stage III NSCLC\nEst
 imated primary completion: April 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07139041
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06941766-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270416
DTEND;VALUE=DATE:20270417
SUMMARY:Iparomlimab and tuvonralimab: Phase 1/2 readout est. (NCT06941766)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 1/2.\nStudy: Iparomlimab a
 nd Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors\nEstimated 
 primary completion: 16 April 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06941766
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07530445-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07530445)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Phase II Study 
 of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound
  Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Meta
 static Biliary Tract Cancer\nEstimated primary completion: 30 April 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvon
 ralimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07530445
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06917092-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT06917092)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706-Based Th
 erapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer\nEstimated prima
 ry completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06917092
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06939855-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT06939855)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 in the T
 reatment of Advanced Bone and Soft Tissue Sarcoma\nEstimated primary compl
 etion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ip
 aromlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06939855
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07014150-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07014150)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Neoadjuvant The
 rapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatoce
 llular Carcinoma\nEstimated primary completion: 1 May 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07014150
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06951997-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT06951997)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 Plus Chi
 damide\, AG as First-line Treatment for Metastatic Pancreatic Cancer\nEsti
 mated primary completion: 15 May 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06951997
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005583-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07005583)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Clinical Study 
 of QL1706 in Combination With Olaparib for the Treatment of Patients With 
 Previously Treated Homologous Recombination Repair-Deficient Recurrent or 
 Metastatic Triple-Negative Breast Cancer\nEstimated primary completion: 30
  May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlima
 b-and-tuvonralimab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07005583
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06967103-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT06967103)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 for the 
 Neoadjuvant Treatment of HR+/HER2- Breast Cancer\nEstimated primary comple
 tion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ip
 aromlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06967103
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07272590-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Iparomlimab and tuvonralimab: Phase 1/2 readout est. (NCT07272590)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 1/2.\nStudy: Study of QLC5
 513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patie
 nts With Advanced or Metastatic Malignant Solid Tumors\nEstimated primary 
 completion: June 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07272590
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07083375-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07083375)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: A Phase II Stud
 y of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-s
 tage Small Cell Lung Cancer.\nEstimated primary completion: 1 June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonr
 alimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07083375
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07002346-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Iparomlimab and tuvonralimab: Phase 3 readout est. (NCT07002346)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 3.\nStudy: INVIGORATE: A S
 tudy of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell C
 arcinoma\nEstimated primary completion: 1 June 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07002346
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156682-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07156682)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 Plus XEL
 OX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer\nEs
 timated primary completion: 30 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07156682
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07150247-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07150247)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Metastatic Colorectal 
 Cancer.\nStudy: Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Met
 astatic Colorectal Cancer\nEstimated primary completion: 30 June 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonral
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07150247
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07769853-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Iparomlimab and tuvonralimab: Phase na readout est. (NCT07769853)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase na.\nStudy: Iparomlimab an
 d Tuvonralimab Combined With Chemotherapy and Bevacizumab as Neoadjuvant T
 herapy for Locally Advanced Rectal Cancer\nEstimated primary completion: 1
  July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlim
 ab-and-tuvonralimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07769853
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07045805-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07045805)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Phase II Study 
 of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune 
 Rechallenge in Gastric Cancer\nEstimated primary completion: 31 July 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvo
 nralimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07045805
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07138885-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07138885)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: A Phase II\, Si
 ngle-Arm\, Prospective Trial on the Efficacy and Safety of QL1706 Combinat
 ion Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant He
 patocellular Carcinoma\nEstimated primary completion: 31 July 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 138885
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07178171-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Iparomlimab and tuvonralimab: Phase 1 readout est. (NCT07178171)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 1.\nStudy: A Study of QL17
 06 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment o
 f Early-Stage TNBC\nEstimated primary completion: 1 August 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07178
 171
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07070700-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07070700)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Cryoablation Co
 mbined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients 
 With Advanced Intrahepatic Cholangiocarcinoma\nEstimated primary completio
 n: 1 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipa
 romlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07070700
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07091305-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07091305)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: A Study of QL17
 06 Combined With Chemotherapy Induction on Sequential Immunotherapy Consol
 idation in Patients With Limited-Stage Small Cell Lung Cancer After Chemor
 adiotherapy\nEstimated primary completion: 1 August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07091305
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07090317-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07090317)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab in HNSCC\nEstimated primary completion: 1 August 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7090317
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07115550-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270826
DTEND;VALUE=DATE:20270827
SUMMARY:Iparomlimab and tuvonralimab: Phase na readout est. (NCT07115550)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase na.\nStudy: A Single-cente
 r\, Single-arm\, Phase II Clinical Study of Iparomlimab and Tuvonralimab I
 njection Combined With Regorafenib in the Treatment of Advanced Second-lin
 e or Above Hepatocellular Carcinoma\nEstimated primary completion: 26 Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-
 and-tuvonralimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07115550
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07160647-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07160647)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: The Efficacy an
 d Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Local
 ly Advanced MSI-H/dMMR Colorectal Cancer: An Prospective\, Single-Arm Stud
 y (Neo-IT)\nEstimated primary completion: 30 August 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07160647
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07116577-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07116577)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Radiotherapy Co
 mbined QL1706\, TAS-102 and Bevacizumab in mCRC\nEstimated primary complet
 ion: 31 August 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07116577
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07110064-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07110064)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706+Lenvatin
 ib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic C
 ancer\nEstimated primary completion: 31 August 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07110064
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07353268-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07353268)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Phase Ib/II Stu
 dy of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unre
 sectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety\, Tolerabilit
 y\, and Efficacy.\nEstimated primary completion: 31 August 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07353
 268
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05487391-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Iparomlimab and tuvonralimab: Phase 3 readout est. (NCT05487391)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 3\, Non-Small Cell Lung Ca
 ncer.\nStudy: A Study of QL1706 Combined With Platinum-containing Chemothe
 rapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer Aft
 er Complete Surgical Resection.\nEstimated primary completion: 31 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-
 tuvonralimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05487391
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07180160-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07180160)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab (QL1706) in Patients With HR-positive\, HER2-negative Advanc
 ed Breast Cancer\nEstimated primary completion: September 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071801
 60
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07289997-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07289997)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the 
 Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)\n
 Estimated primary completion: September 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07289997
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776639-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07776639)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy 
 for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Ju
 nction\nEstimated primary completion: September 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07776639
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05976568-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Iparomlimab and tuvonralimab: Phase 2/3 readout est. (NCT05976568)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2/3.\nStudy: A Study of QL
 1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Tre
 atment in Patients With Advanced Hepatocellular Carcinoma\nEstimated prima
 ry completion: 1 September 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05976568
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07601178-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07601178)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QUEEN-APPLE: A 
 Single-Arm\, Multicenter\, Prospective Phase II Clinical Study of Iparomli
 mab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride 
 and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Br
 east Cancer\nEstimated primary completion: 15 September 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07601178
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06884982-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT06884982)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: An Exploratory 
 Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with Q
 L1706 Combined with Lenvatinib\nEstimated primary completion: 30 September
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-an
 d-tuvonralimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06884982
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286240-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07286240)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 Combined
  With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Ca
 ncer\nEstimated primary completion: 30 September 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07286240
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286253-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07286253)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 Plus Che
 motherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A P
 hase II Trial\nEstimated primary completion: 30 September 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072862
 53
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509515-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07509515)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QLC5513 Alone o
 r in Combination With QL1706 in Previously Treated Advanced or Metastatic 
 TNBC.\nEstimated primary completion: 30 September 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07509515
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134413-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07134413)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Non-Small Cell Lung Ca
 ncer.\nStudy: QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous 
 NSCLC\nEstimated primary completion: October 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07134413
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07141186-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07141186)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 in Patie
 nts With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/
 PD-L1 Antibody Therapy\nEstimated primary completion: 1 October 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonrali
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07141186
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776080-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07776080)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab With Lenvatinib\, Radiotherapy\, and HAIC for Hepatocellular
  Carcinoma With Portal Vein Tumor Thrombus\nEstimated primary completion: 
 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparo
 mlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07776080
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07129018-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07129018)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Trastuzumab Rez
 etecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Bilia
 ry Tract Cancer\nEstimated primary completion: November 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07129018
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07197697-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07197697)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: A Phase II Expl
 oratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy i
 n Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients\nEstimated pri
 mary completion: 1 November 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07197697
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07343791-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Iparomlimab and tuvonralimab: Phase 1 readout est. (NCT07343791)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 1.\nStudy: Efficacy and Sa
 fety Study of DC-CIK Cell Therapy Combined With Epaloliposide\, Vortexil\,
  and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.\n
 Estimated primary completion: 30 November 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07343791
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392346-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07392346)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Safety and Effi
 cacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab 
 Injection in the Second-Line Treatment for Immunotherapy-experienced Advan
 ced Gastric Cancer\nEstimated primary completion: 30 November 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 392346
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06882447-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT06882447)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: A Study of QL17
 06 Combined with Nine HPV Vaccine As First-line Treatment for Persistent\,
  Recurrent or Metastatic Cervical Cancer\nEstimated primary completion: De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparomli
 mab-and-tuvonralimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06882447
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082179-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07082179)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Non-Small Cell Lung Ca
 ncer.\nStudy: A Prospective Phase II Clinical Study of Immunotherapy Combi
 ned With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cance
 r\nEstimated primary completion: December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07082179
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07179900-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07179900)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Radiotherapy Co
 mbined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatoc
 ellular Carcinoma\nEstimated primary completion: December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071799
 00
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07200947-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07200947)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Non-Small Cell Lung Ca
 ncer.\nStudy: A Phase II Study of QL1706 and Platinum-Based Chemotherapy i
 n Patients With SMARCA4-Deficient\, Locally Advanced or Metastatic Non-Sma
 ll Cell Lung Cancer.\nEstimated primary completion: 1 December 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7200947
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06893887-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Iparomlimab and tuvonralimab: Phase na readout est. (NCT06893887)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase na.\nStudy: Individualized
  Comprehensive Treatment for Advanced Hepatocellular Carcinoma\nEstimated 
 primary completion: 15 December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06893887
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286942-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271218
DTEND;VALUE=DATE:20271219
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07286942)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Non-Small Cell Lung Ca
 ncer.\nStudy: Stereotactic Body Radiotherapy With Sequential Iparomlimab a
 nd Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients
  With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a S
 ingle-arm\, Single-centre\, Phase 2 Trial\nEstimated primary completion: 1
 8 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipar
 omlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07286942
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07342283-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271225
DTEND;VALUE=DATE:20271226
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07342283)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 Plus Che
 motherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer\nEstimat
 ed primary completion: 25 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07342283
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07148427-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07148427)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Immunotherapy C
 ombined With Anti-angiogenic Therapy and Chemotherapy for Gastric/Gastroes
 ophageal Junction Adenocarcinoma\nEstimated primary completion: 30 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-a
 nd-tuvonralimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07148427
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07327788-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07327788)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 in Combi
 nation With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With V
 p3/4 PVTT\nEstimated primary completion: 30 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07327788
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416058-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07416058)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Non-Small Cell Lung Ca
 ncer.\nStudy: PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Res
 istant\, PD-L1 ≥50% Non-Squamous NSCLC\nEstimated primary completion: 30
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparo
 mlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07416058
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07085234-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07085234)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab/Tuv
 orlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07085234
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07205185-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07205185)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: A Multicenter\,
  Single-arm\, Prospective Phase II Clinical Study of Epalrotokewali Combin
 ed With Eribulin\, Anlotinib\, and Radiotherapy for the Treatment of Patie
 nts With Advanced Soft Tissue Sarcoma.\nEstimated primary completion: 31 D
 ecember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparoml
 imab-and-tuvonralimab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07205185
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07246317-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07246317)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Evaluation of N
 eoadjuvant Therapy With Trastuzumab\, Pertuzumab\, Docetaxel\, and QL1706 
 in Early or Locally Advanced HER2+ Breast Cancer\nEstimated primary comple
 tion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07246317
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07315854-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07315854)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated
  Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer\nEstim
 ated primary completion: 31 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07315854
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07349225-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07349225)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic
  Radiotherapy for Extensive-Stage Small Cell Lung Cancer\nEstimated primar
 y completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07349225
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07369986-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07369986)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Immunotherapy f
 or Surgery Avoidance in Vulnerable dMMR Endometrial Cancer\nEstimated prim
 ary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07369986
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389629-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07389629)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy 
 for ccRCC\nEstimated primary completion: 31 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07389629
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407452-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07407452)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined Wit
 h Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Thera
 py for Advanced Ovarian Cancer\nEstimated primary completion: 31 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and
 -tuvonralimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07407452
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07447570-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07447570)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHN
 SCC\nEstimated primary completion: 31 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07447570
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07530549-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07530549)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: A Phase II Sing
 le-arm Clinical Study in the Treatment of Locally Advanced Esophageal Canc
 er After Failed Neoadjuvant Chemoimmunotherapy\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07530549
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07127822-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07127822)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Assessing Iparo
 mlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Canc
 er\nEstimated primary completion: 31 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07127822
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07546383-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Iparomlimab and tuvonralimab: Phase na readout est. (NCT07546383)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase na.\nStudy: A Study Invest
 igating the Efficacy and Safety of the Combination of Iparomlimab and Tuvo
 nralimab With or Without Chemotherapy in Second-line and Subsequent Treatm
 ents for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma\nEs
 timated primary completion: 31 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07546383
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07330596-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280128
DTEND;VALUE=DATE:20280129
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07330596)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Non-Small Cell Lung Ca
 ncer.\nStudy: QL1706 Combined With Chemotherapy in the Treatment of Immune
 -mediated NSCLC\nEstimated primary completion: 28 January 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073305
 96
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07128251-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07128251)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: A Single-Arm\, 
 Multicenter\, Exploratory Clinical Study of Transarterial Chemoembolizatio
 n (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizu
 mab Injection for the Treatment of Unresectable\, Non-Metastatic Hepatocel
 lular Carcinoma (HCC)\nEstimated primary completion: 30 January 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonrali
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07128251
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07070713-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07070713)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Metastatic Colorectal 
 Cancer.\nStudy: Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Beva
 cizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC\nEstim
 ated primary completion: 28 February 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07070713
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07152769-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07152769)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab Combined With GC in Advanced ICC\nEstimated primary completi
 on: 29 February 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07152769
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06829797-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT06829797)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: A Multicenter R
 andomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL170
 6) Combined With SOX Chemotherapy Versus Chemotherapy Alone in the Treatme
 nt of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
 \nEstimated primary completion: 29 February 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06829797
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06789796-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Iparomlimab and tuvonralimab: Phase 3 readout est. (NCT06789796)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 3.\nStudy: a Study of QL17
 06 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After C
 hemoradiotherapy.\nEstimated primary completion: March 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06789796
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931873-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Iparomlimab and tuvonralimab: Phase 1 readout est. (NCT06931873)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 1.\nStudy: Neoadjuvant Rad
 iochemotherapy Combined With QL1706 for Low Rectal Cancer\nEstimated prima
 ry completion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06931873
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07542717-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Iparomlimab and tuvonralimab: Phase 1/2 readout est. (NCT07542717)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 1/2.\nStudy: ASCERV Study:
  MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer\nE
 stimated primary completion: 31 March 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07542717
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06878222-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT06878222)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therap
 y for CC\nEstimated primary completion: 31 March 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06878222
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07263360-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07263360)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion T
 herapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinom
 a and Gallbladder Cancer\nEstimated primary completion: 31 March 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonral
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07263360
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502027-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Iparomlimab and tuvonralimab: Phase 4 readout est. (NCT07502027)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 4.\nStudy: A Clinical Stud
 y of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneou
 s Radiotherapy as First-line Treatment for Unresectable Locally Advanced o
 r Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarci
 noma\nEstimated primary completion: 31 March 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07502027
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07135804-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07135804)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carc
 inoma\nEstimated primary completion: 30 April 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07135804
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07515469-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07515469)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: A Prospective\,
  Single-Arm\, Exploratory Study of the Safety and Efficacy of Neoadjuvant 
 Treatment With QL1706\, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody\, in 
 Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence 
 Risk\nEstimated primary completion: 30 May 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07515469
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06949111-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT06949111)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Radiotherapy + 
 Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Ne
 o-Color）\nEstimated primary completion: 30 May 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06949111
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07733115-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07733115)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706（Iparom
 limab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line 
 Treatment for PD-L1-Positive Biliary Tract Cancer\nEstimated primary compl
 etion: 1 June 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/i
 paromlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07733115
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07782840-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07782840)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 Plus Neo
 adjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With
  a Poor Response to Neoadjuvant Chemotherapy\nEstimated primary completion
 : 1 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparom
 limab-and-tuvonralimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07782840
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07617818-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07617818)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 Combined
  With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer\nEst
 imated primary completion: 15 June 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07617818
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07187674-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Iparomlimab and tuvonralimab: Phase na readout est. (NCT07187674)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase na.\nStudy: The Neoadjuvan
 t Treatment of Early High-risk Triple Negative Breast Cancer With HRD Posi
 tive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitax
 el\nEstimated primary completion: 15 June 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07187674
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06936748-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280619
DTEND;VALUE=DATE:20280620
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT06936748)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: SFRT+Sequential
  Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralima
 b for Relapsed/Refractory Solid Tumors\nEstimated primary completion: 19 J
 une 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab
 -and-tuvonralimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06936748
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07256236-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07256236)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: SKB264 Plus QL1
 706 in Recurrent or Metastatic Cervical Cancer\nEstimated primary completi
 on: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipa
 romlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07256236
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07533305-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07533305)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Efficacy and Sa
 fety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Ther
 apy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma\nEstimat
 ed primary completion: 30 June 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07533305
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07841574-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07841574)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: HAIC Plus QL170
 6 & Bevacizumab in Unresectable HER2-Negative ICC\nEstimated primary compl
 etion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07841574
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874438-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Iparomlimab and tuvonralimab: Phase na readout est. (NCT07874438)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase na\, Metastatic Colorectal
  Cancer.\nStudy: A Prospective\, Single-Arm\, Multicenter\, Phase II Clini
 cal Study of Iparomlimab and Tuvonralimab (QL1706) Combined With Cetuximab
  and mFOLFIRI Regimen as First-Line Treatment for Recurrent or Metastatic 
 Colorectal Cancer\nEstimated primary completion: 30 June 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0787443
 8
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07025239-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Iparomlimab and tuvonralimab: Phase 3 readout est. (NCT07025239)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 3\, Metastatic Colorectal 
 Cancer.\nStudy: QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plu
 s Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic
  Colorectal Cancer\nEstimated primary completion: July 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07025239
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07595523-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07595523)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab Tol
 vorlimab as Neoadjuvant Immunotherapy for Locally Advanced Gastric Adenoca
 rcinoma With Microsatellite Instability/Mismatch Repair Deficiency\nEstima
 ted primary completion: 1 July 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07595523
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07041788-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280709
DTEND;VALUE=DATE:20280710
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07041788)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locor
 egionally Advanced Bulky HNSCC\nEstimated primary completion: 9 July 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvo
 nralimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07041788
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07101744-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280716
DTEND;VALUE=DATE:20280717
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07101744)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC Aft
 er First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial\nEs
 timated primary completion: 16 July 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07101744
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07866313-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Iparomlimab and tuvonralimab: Phase 2/3 readout est. (NCT07866313)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2/3.\nStudy: Neoadjuvant C
 hemoradiotherapy Combined With QL1706 for MSS-Type Low-Rectal Cancer\nEsti
 mated primary completion: 1 August 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07866313
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07741617-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07741617)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: A Prospective\,
  Single-Arm\, Multicenter Clinical Study of High-Risk Localized and Locall
 y Advanced Renal Clear Cell Carcinoma\nEstimated primary completion: 15 Au
 gust 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlima
 b-and-tuvonralimab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07741617
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07833241-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07833241)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Surufatinib in 
 Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherap
 y for Neoadjuvant Therapy of HRPC or BRPC\nEstimated primary completion: 1
  September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipar
 omlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07833241
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829874-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280920
DTEND;VALUE=DATE:20280921
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07829874)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Cryoablation Co
 mbined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients 
 With Advanced Biliary Tract Cancer.\nEstimated primary completion: 20 Sept
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlim
 ab-and-tuvonralimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07829874
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07165847-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20280923
DTEND;VALUE=DATE:20280924
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07165847)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Neoadjuvant Rad
 iotherapy Plus Tegafur\, Oxaliplatin and Iparomlimab and Tuvonralimab in R
 esectable Gastric and GE-junction Cancer : A Randomized\, Two-arm\, Prospe
 ctive Trial (TRIUNITE-05)\nEstimated primary completion: 23 September 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuv
 onralimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07165847
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07882888-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281016
DTEND;VALUE=DATE:20281017
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07882888)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab With With Cetuximab in Resectable OSCC\nEstimated primary co
 mpletion: 16 October 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07882888
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07490002-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07490002)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Neoadjuvant The
 rapy With Iparomlimab and Tuvonralimab\, Lenvatinib and Chemotherapy in Re
 sectable ESCC\nEstimated primary completion: 30 November 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0749000
 2
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07151209-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07151209)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Immunotherapy C
 ombined With Anti-angiogenic Therapy and Chemotherapy for Potentially Rese
 ctable MSI-H\, dMMR Locally Advanced Gastric or Gastroesophageal Junction 
 Adenocarcinoma\nEstimated primary completion: December 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07151209
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07452003-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Iparomlimab and tuvonralimab: Phase na readout est. (NCT07452003)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase na\, Non-Small Cell Lung C
 ancer.\nStudy: An Exploratory Study of QL1706 Plus Chemotherapy in Periope
 rative NSCLC\nEstimated primary completion: December 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07452003
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07646301-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07646301)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Loca
 lly Advanced Cervical Cancer\nEstimated primary completion: 1 December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tu
 vonralimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07646301
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06749899-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Iparomlimab and tuvonralimab: Phase 3 readout est. (NCT06749899)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 3.\nStudy: QL1706 (PD-1/CT
 LA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advance
 d Nasopharyngeal Carcinoma.\nEstimated primary completion: 1 December 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuv
 onralimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06749899
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07372079-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07372079)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Neoadjuvant The
 rapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach U
 sing Iparomlimab and Tuvonralimab Injection in Combination With Chemothera
 py\nEstimated primary completion: 30 December 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07372079
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636226-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Iparomlimab and tuvonralimab: Phase 2/3 readout est. (NCT07636226)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2/3.\nStudy: QL1706 Plus A
 nlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer\
 nEstimated primary completion: 30 December 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07636226
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07729605-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Iparomlimab and tuvonralimab: Phase 3 readout est. (NCT07729605)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 3.\nStudy: FOLFIRI Plus Be
 vacizuamb and QL1706 in Second-Line Treatment for mCRC\nEstimated primary 
 completion: 30 December 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07729605
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07315035-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07315035)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706-SOX vs S
 OX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer
 \nEstimated primary completion: 31 December 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07315035
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07400315-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07400315)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: First-line Trea
 tment of Gastric or Gastroesophageal Junction Adenocarcinoma With Dual Imm
 unotherapy Combined With Chemotherapy\nEstimated primary completion: 31 De
 cember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparomli
 mab-and-tuvonralimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07400315
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502014-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07502014)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Metastatic Colorectal 
 Cancer.\nStudy: A Clinical Study of Iparomlimab and Tuvonralimab Combined 
 With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Th
 ird-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer\nE
 stimated primary completion: 31 December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07502014
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446387-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07446387)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Metastatic Colorectal 
 Cancer.\nStudy: A Clinical Study of Iparomlimab and Tuvonralimab Combined 
 With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-
 line Treatment for Unresectable Advanced Colorectal Cancer\nEstimated prim
 ary completion: 31 December 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07446387
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07649473-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07649473)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 Combined
  With Standard Therapy for Conversion Therapy of Synchronous Liver Metasta
 ses From Colon Cancer: a Multicenter\, Single-arm\, Exploratory Study\nEst
 imated primary completion: 31 December 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07649473
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07673835-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07673835)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer
 （Phase II）\nEstimated primary completion: 31 December 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076738
 35
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06954116-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT06954116)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcino
 ma With High Risk of Recurrence\nEstimated primary completion: 31 December
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-an
 d-tuvonralimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06954116
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07847359-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07847359)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Cryoablation Co
 mbined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1
 706)\, Intravenous Dacarbazine\, and Oral Lenvatinib in Patients With Live
 r Metastases From Malignant Melanoma: a Single-arm\, Phase II\, Prospectiv
 e Trial\nEstimated primary completion: 31 December 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07847359
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07938658-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07938658)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab Injection （QL1706）Combined With Chemotherapy (AG) and SB
 RT as First-Line Treatment for Locally Advanced Pancreatic Cancer\nEstimat
 ed primary completion: 31 December 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07938658
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07004335-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Iparomlimab and tuvonralimab: Phase 4 readout est. (NCT07004335)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 4.\nStudy: Efficacy and Sa
 fety of Iparomlimab and Tuvonralimab Injection in Combination With Bevaciz
 umab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Pro
 spective\, Single-Arm\, Exploratory Clinical Study\nEstimated primary comp
 letion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07004335
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07328009-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07328009)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: A Platform Tria
 l for Personalized and Adaptive Therapies in Hepatocellular Carcinoma\nEst
 imated primary completion: 15 January 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07328009
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07384416-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07384416)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 Plus Len
 vatinib in Previously Treated Penile Cancer\nEstimated primary completion:
  1 February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipa
 romlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07384416
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07413601-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20290210
DTEND;VALUE=DATE:20290211
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07413601)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Phase 2 Clinica
 l Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Plati
 num Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/
 Third-line Triple Negative Breast Cancer (TNBC)\nEstimated primary complet
 ion: 10 February 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07413601
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07663513-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07663513)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadj
 uvant Therapy for Advanced Ovarian Cancer\nEstimated primary completion: A
 pril 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlima
 b-and-tuvonralimab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07663513
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07538193-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Iparomlimab and tuvonralimab: Phase na readout est. (NCT07538193)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase na\, Non-Small Cell Lung C
 ancer.\nStudy: Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surge
 ry for Stage III Lung Cancer\nEstimated primary completion: May 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonrali
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07538193
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07863869-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20290527
DTEND;VALUE=DATE:20290528
SUMMARY:Iparomlimab and tuvonralimab: Phase 1/2 readout est. (NCT07863869)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 1/2.\nStudy: The QL1706 Co
 mbined With Chemotherapy and Either Cetuximab or Bevacizumab in Potentiall
 y Resectable Colorectal Cancer Patients With Liver Metastases\nEstimated p
 rimary completion: 27 May 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07863869
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05690945-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Iparomlimab and tuvonralimab: Phase 3 readout est. (NCT05690945)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 3\, Non-Small Cell Lung Ca
 ncer.\nStudy: A Study of QL1706 in Combination With Chemotherapy in PD-L1-
 Negative Non-small Cell Lung Cancer\nEstimated primary completion: June 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-t
 uvonralimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05690945
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07379398-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07379398)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Non-Small Cell Lung Ca
 ncer.\nStudy: Iparomlimab and Tuvonralimab Injection Combined With SBRT in
  Patients With Early-Stage Non-Small Cell Lung Cancer\nEstimated primary c
 ompletion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07379398
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668570-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Iparomlimab and tuvonralimab: Phase 4 readout est. (NCT07668570)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 4.\nStudy: SBRT Plus QL170
 6 as Second-Line Therapy for Hepatocellular Carcinoma\nEstimated primary c
 ompletion: July 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07668570
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686640-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20290715
DTEND;VALUE=DATE:20290716
SUMMARY:Iparomlimab and tuvonralimab: Phase 3 readout est. (NCT07686640)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 3.\nStudy: Short-Course Ra
 diotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab 
 in pMMR/MSS Locally Advanced Rectal Cancer\nEstimated primary completion: 
 15 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparoml
 imab-and-tuvonralimab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07686640
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07828873-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07828873)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: A Single-Arm St
 udy of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advance
 d Gastric/GEJ Adenocarcinoma\nEstimated primary completion: September 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuv
 onralimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07828873
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07854522-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Iparomlimab and tuvonralimab: Phase 4 readout est. (NCT07854522)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 4.\nStudy: A Study of QL17
 06 Combined With OH2 Injection in Perioperative Treatment of Stage III Res
 ectable Acral Melanoma\nEstimated primary completion: September 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonrali
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07854522
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07847671-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07847671)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Fecal Microbiot
 a Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC\n
 Estimated primary completion: October 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07847671
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07277972-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07277972)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the
  Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcino
 ma That Has Failed First-Line Systemic Therapy\nEstimated primary completi
 on: 30 November 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07277972
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933016-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07933016)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 and Lenv
 atinib Combined With FOLFOX Systemic Chemotherapy as Second-line Treatment
  in Advanced Hepatocellular Carcinoma Patients\nEstimated primary completi
 on: 1 December 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07933016
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06864013-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT06864013)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: SCRT Combined W
 ith Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients 
 With Locally Advanced Rectal Cancer\nEstimated primary completion: 31 Dece
 mber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlima
 b-and-tuvonralimab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06864013
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07383285-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07383285)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: CAPOX and Bevac
 izumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvo
 nralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Canc
 er\nEstimated primary completion: 31 December 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07383285
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622836-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Iparomlimab and tuvonralimab: Phase na readout est. (NCT07622836)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase na.\nStudy: A Prospective\
 , Multicenter\, Phase II Clinical Study of Postoperative Chemotherapy Comb
 ined With QL1706 for High-risk Triple-negative Breast Cancer.\nEstimated p
 rimary completion: 31 January 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07622836
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07940478-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20300301
DTEND;VALUE=DATE:20300302
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07940478)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: A Single-Arm\, 
 Exploratory\, Phase II Study of Iparomlimab and Tuvonralimab Combined With
  Local Therapy as First-Line Treatment for Hepatocellular Carcinoma With P
 ortal Vein Tumor Thrombus\nEstimated primary completion: 1 March 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonral
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07940478
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07882056-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07882056)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: SBRT Combined W
 ith Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellul
 ar Carcinoma\nEstimated primary completion: August 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07882056
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07738159-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20300801
DTEND;VALUE=DATE:20300802
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07738159)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: Iparomlimab and
  Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary
  Neuroendocrine Carcinoma\nEstimated primary completion: 1 August 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonra
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07738159
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06852456-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT06852456)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2.\nStudy: QL1706 in Combi
 nation With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for L
 ocally Advanced\, Resectable Esophageal Squamous Cell Carcinoma\nEstimated
  primary completion: December 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06852456
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06686576-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Iparomlimab and tuvonralimab: Phase 3 readout est. (NCT06686576)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 3.\nStudy: A Study of Neoa
 djuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon 
 Cancer\nEstimated primary completion: December 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06686576
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07613567-2261@assetmemo.bio
DTSTAMP:20261121T005035Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Iparomlimab and tuvonralimab: Phase 3 readout est. (NCT07613567)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 3.\nStudy: QL1706 Combined
  With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced C
 ervical Cancer\nEstimated primary completion: 31 December 2032. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076135
 67
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
